Skip to main content

Table 1 Literature search criteria

From: The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach



Research Question

“How has the COVID-19 pandemic impacted the ability of adult individuals diagnosed with schizophrenia or bipolar I disorder to access appropriate treatment, including the use of a long-acting injectable antipsychotic?”

Individual Population

Adults aged ≥18 years. Literature Database Categories: Adult (18+ years); Young Adult (19–24 years); Adult (19–44 years); Middle Aged (45–64 years); Aged (65+ years); 80 and over (80+ years)

Therapeutic Indication

Schizophrenia; Bipolar I Disorder

Journal Type




Types of Evidence

Case Report; Observation Study; Clinical Study; Clinical Trial; Randomized Controlled Trial; Multicenter Study; Observational Study; Meta-analysis; Systematic Review

Literature Databases

PubMed; OVID Medline; CINAHL

Literature Type

Full text; Free Full Text; Open Access

Time Period

January 1, 2020 – March 10, 2021